Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366332 | 1.00 | GPR84 (1.00) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL29726541 | 1.00 | GPR84 (1.00) | GPR84MEN1KMT2AKDM4ERECQL | |
| Alcohol SCHEMBL15876328 | 0.92 | GPR84 (0.84) | GPR84MEN1KMT2AKDM4ERECQL | |
| Pyridine SCHEMBL31748578 | 0.89 | GPR84 (0.79) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL18965878 | 0.87 | GPR84 (0.75) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL21615657 | 0.84 | GPR84 (0.82) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL15198302 | 0.83 | GPR84 (0.69) | GPR84MEN1KMT2AKDM4ERECQL | |
| SCHEMBL31280085 | 0.81 | GPR84 (0.69) | GPR84MEN1KMT2AKDM4E | |
| SCHEMBL3967442 | 0.81 | GPR84 (0.69) | GPR84MEN1KMT2AKDM4E | |
| SCHEMBL887345 | 0.81 | GPR84 (0.69) | GPR84MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 756 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4265604-B1 | OXASPIRO SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2026-04-01 | — | — | EP | claimed |
| EP-4431548-B1 | METHOD FOR PREPARING COMB POLYMER AND USE THEREOF FOR FORMING SOLID ELECTROLYTE | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2025-06-25 | — | — | EP | claimed |
| EP-4431549-B1 | METHOD FOR PREPARING COMB POLYMER AND USE THEREOF FOR FORMING SOLID ELECTROLYTE | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2025-06-25 | — | — | EP | claimed |
| WO-2024130425-A1 | METHODS OF MAKING 2-AMINO-L-(3-HYDROXY-2,6-DIMETHYLPHENYL)-5,6- DIMETHYL-LH-PYRROLO-[2,3-B]PYRIDINE-3-CARBOXAMIDE, A MYTL INHIBITOR | REPARE THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | claimed |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20240109895-A1 | OXASPIRO SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-04-04 | — | — | US | claimed |
| EP-4265604-A1 | OXASPIRO SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2023-10-25 | — | — | EP | claimed |
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| US-20220315588-A1 | ALTERNATIVE PROCESS FOR THE PREPARATION OF 4-PHENYL-5-ALKOXYCARBONYL-2-THIAZOL-2-YL-1,4-DIHYDROPYRIMIDIN-6-YL]METHYL]-3-OXO-5,6,8,8A-TETRAHYDRO-1H-IMIDAZO[1,5-A]PYRAZIN-2-YL]-CARBOXYLIC ACID | HOFFMANN-LA ROCHE INC. (US) | 2022-10-06 | — | — | US | claimed |
| EP-3954691-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERIC DERIVATIVES 4-PHENYL-6-METHYL-5-ALKOXYCARBONYL-2-THIAZOL-2-YL-1,4-DIHYDROPYRIMIDINE | F. Hoffmann-La Roche AG (CH) | 2022-02-16 | — | — | EP | claimed |
| US-20040192727-A1 | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer | PFIZER INC. | 2004-09-30 | — | — | US | claimed |
| US-6740757-B2 | ANTICANCER AGENTS | PFIZER INC | 2004-05-25 | — | — | US | claimed |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | claimed |
| WO-2003021355-A9 | ENANTIOMERS OF 6-[(4-CHLORO-PHENYL)-HYDROXY-(3-METHYL-3H-IMIDAZOL-4-YL)-METHYL]4-[3-(3-HYDROXY-3-METHYL-BUT-1-YNYL)-PHENYL]-1-METHYL-1H-QUINOLIN-2-ONE AND SALTS THEREOF, USEFUL IN THE TREATMENT OF CANCER | OSI PHARM INC (US) | 2003-07-10 | — | — | WO | claimed |
| US-20030114487-A1 | Enantiomers of 6-[(4-chloro-phenyl)- hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1- methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer | PFIZER INC. | 2003-06-19 | — | — | US | claimed |
| WO-2003021355-A1 | ENANTIOMERS OF 6-[(4-CHLORO-PHENYL)-HYDROXY-(3-METHYL-3H-IMIDAZOL-4-YL)-METHYL]4-[3-(3-HYDROXY-3-METHYL-BUT-1-YNYL)-PHENYL]-1-METHYL-1H-QUINOLIN-2-ONE AND SALTS THEREOF, USEFUL IN THE TREATMENT OF CANCER | OSI PHARMACEUTICALS, INC. (US) | 2003-03-13 | — | — | WO | claimed |
| US-6162919-A | Process for preparing the d-threo isomer of methylphenidate hydrochloride | NOVARTIS AG (CH) | 2000-12-19 | — | — | US | claimed |
| EP-0181529-B1 | Optically active 2-(4-chloro-phenoxymethly)-3, 3-dimethyl-1-(1,2,4-triazol-1-yl)-2-butanol, process for its preparation as well as its use as an antimycotic agent. | BAYER AG (DE) | 1991-03-27 | — | — | EP | claimed |
| US-4783538-A | PLANT GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1988-11-08 | — | — | US | claimed |
| EP-0181529-A2 | Optically active 2-(4-chloro-phenoxymethly)-3, 3-dimethyl-1-(1,2,4-triazol-1-yl)-2-butanol, process for its preparation as well as its use as an antimycotic agent. | BAYER AG (DE) | 1986-05-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315588-A1 | ALTERNATIVE PROCESS FOR THE PREPARATION OF 4-PHENYL-5-ALKOXYCARBONYL-2-THIAZOL-2-YL-1,4-DIHYDROPYRIMIDIN-6-YL]METHYL]-3-OXO-5,6,8,8A-TETRAHYDRO-1H-IMIDAZO[1,5-A]PYRAZIN-2-YL]-CARBOXYLIC ACID | ZC3HAV1L, ZC3HAV1, XDH | GPR84 3094/4885MEN1 2503/4885KMT2A 1764/4885 |
| US-20240109895-A1 | OXASPIRO SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, INTERMEDIATE THEREOF, AND PREPARATION METHOD THEREFOR | WEE1, OXA1L, FARS2 | GPR84 4534/4885MEN1 2509/4885KMT2A 4237/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | GPR84 4479/4885MEN1 2672/4885KMT2A 1545/4885 |
| US-20040030145-A1 | Optically active B-aminoketones, optically active 1,3-amino alcohols and processes for preparing them | ORMDL3, OR10J3, BCAT2 | GPR84 1594/4885MEN1 3531/4885KMT2A 2885/4885 |
| US-20030114487-A1 | Enantiomers of 6-[(4-chloro-phenyl)- hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1- methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer | BPNT1, TK1, PHPT1 | GPR84 3868/4885MEN1 2132/4885KMT2A 915/4885 |
| US-20040192727-A1 | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer | BPNT1, TK1, PHPT1 | GPR84 3996/4885MEN1 2107/4885KMT2A 833/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | GPR84 4454/4885MEN1 2073/4885KMT2A 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.